Rebalix
iShares · sheet of 4 September 2026
iShares · sheet of 4 September 2026ETF sheet · official issuer and register data
iShares $ Treasury Bond 3-7yr UCITS ETF
CBU7 · IE00B3VWN393 · USD · domicile Ireland
Bonds · Government · 3-7 years · North AmericaSFDR art. 6
Index tracked: ICE U.S. Treasury 3-7 Year Bond Index
- TER
- 0.07%+ trans. 0.00%
- Fund size
- 7 bn EUR
- Tracking difference
- +0.07%3-year avg
- 🇮🇹 tax rate
- 13.02%white list 96.18%
- Replication
- Physical (optimised)
- Income
- Accumulating
- Duration
- 4.22 yrsmedium (3–7 years)
Launch 3 Jun 2009 · costs from the KID as of 2 Sept 2026 · 87 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund’s assets, which reflects the return of the ICE U.S. Treasury 3-7 Year Bond Index, the Fund’s benchmark index (Index). The Share Class, via the Fund is passively managed and aims to invest so far as possible and practicable in the fixed income (FI) securities (such as bonds) that make up the Index and comply with its credit rating requirements. If the credit ratings of the FI securities are…
Performance since series start (in euro) — base 100
2 Jul 2009 → 31 Aug 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +1.4% |
| 3 years | +5.2% |
| 5 years | +2.7% |
| 10 years | +9.5% |
| Since series start | +72.3% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 2.89% | 3.88% | 4.75% |
| Max drawdown | −2.46% | −3.63% | −13.41% |
| Sharpe | -0.48 | 0.21 | -0.45 |
| Sortino | -0.65 | 0.30 | -0.64 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · CBU7 · IE00B3VWN3931
RebalixCBU7 · IE00B3VWN393 · sheet of 4 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +7.21% | +7.16% | +0.05% |
| 2024 | +1.93% | +1.92% | +0.01% |
| 2023 | +4.50% | +4.34% | +0.16% |
| 2022 | −9.48% | −9.32% | −0.15% |
| 2021 | −2.43% | −2.40% | −0.03% |
Fixed income — as declared by the issuer
Issuer page · 20 Aug 2026 · investment-grade share (BBB−/Baa3 and above): 99.8%
Rating breakdown (% of fund)
Maturity breakdown (% of fund)
Holdings
Portfolio as declared by the issuer · 31 Aug 2026 · 87 securities · top-10 weight = 19.6%
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
CSBGU7 · Borsa Italiana (ETFplus)
SXRL · Börse Düsseldorf, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Xetra (Deutsche Börse)
CBU7 · Euronext Amsterdam
+ 17 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00B3VWN393
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00B3VWN393
Series, distributions, holdings and documents refresh daily.
Sheet produced on 4 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · CBU7 · IE00B3VWN3932